What are the practical challenges in use of novel intravenous P2Y12 receptor inhibitor 'Cangrelor' in adjunct to PCI? What are the advantages and disadvantages as compared to other anti-platelets?

More Divyanshu Prajapati's questions See All
Similar questions and discussions